Hope for Primary Central Nervous System Lymphoma (PCNSL)
Current treatment options for primary CNS lymphoma (PCNSL) are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with PCNSL.
The PROSPECT study is a clinical trial to evaluate an investigational oral medicine called tirabrutinib* in patients with PCNSL. About 112 participants will be enrolled in the Phase II (PROSPECT) study in the United States.
ANSWER A FEW QUESTIONS TO SEE IF YOU MAY BE ABLE TO PARTICIPATE!
Are you at least 18 years of age?
Have you been diagnosed with Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)?
By choosing to volunteer, you can help make a difference for thousands of others diagnosed with PCNSL.
*Tirabrutinib has been approved and is currently marketed in Japan for R/R PCNSL patients.
Get The New EBCI App
We know how important it is to find the information you are looking for when navigating a Brain Tumor diagnosis for yourself or a loved one. This app has the latest information on:
- Clinical trials
- Patient resources